Asia-Pacific Immunodiagnostics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product [Enzyme-Linked Immunosorbent Assays (ELISA), Chemiluminescence Immunoassays (CLIA), Radioimmunoassays (RIA), and Others], Clinical Indication (Infe

Asia-Pacific Immunodiagnostics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product [Enzyme-Linked Immunosorbent Assays (ELISA), Chemiluminescence Immunoassays (CLIA), Radioimmunoassays (RIA), and Others], Clinical Indication (Infectious Diseases, Hepatitis+HIV, Endocrinology, Gastrointestinal, Metabolics, and Others), and End User (Hospitals, Clinics, Diagnostic Laboratories, Academic & Research Institutes, and Others)

The APAC immunodiagnostics market is expected to grow from US$ 2,231.31 million in 2022 to US$ 3,587.50 million by 2028; it is estimated to grow at a CAGR of 8.2% from 2022 to 2028.

Increasing Prevalence of Infectious Diseases Supports APAC Immunodiagnostics Market Growth

The diagnosis and management of several ever-growing infectious diseases caused by infectious agents such as viruses, fungi, bacteria, parasites, or their toxic products are increasing the number of prescriptions for immunodiagnostic tests—complement fixation, precipitation tests, agglutination tests, line blot assays, western blot assays, enzyme immunoassays (EIA), and immunofluorescence tests. For instance, according to the World Health Organization (WHO), approximately 58 million people worldwide suffer from chronic hepatitis C infection, with 1.5 million new conditions occurring every year. Approximately 3.2 million adolescents and children suffer from this infection. Diagnostics play a vital role in determining the direction of any medical treatment. Immunodiagnostics help diagnose diseases that severely impact the immune system. All these factors indicate that the rising prevalence of infectious diseases leads to the surging demand for immunodiagnostic products, which is supporting the APAC immunodiagnostics market .

APAC Immunodiagnostics Market Overview

Asia Pacific (APAC) is the fastest-growing market for immunodiagnostics. The APAC immunodiagnostic market is segmented into China, India, Japan, South Korea, Australia, and the Rest of APAC. The increasing prevalence of chronic illness in APAC is boosting the demand for diagnostic tests that provide essential details of medical care with detection, diagnostics, and therapy related to the disease. During 2010–2020, APAC witnessed a 39% increase in the number of immunology trials, a significant rise as compared to other regions. In 2020, the maximum number of immunology trials occurred in China, followed by Japan and India. According to Statista, a large chunk of the Chinese population was suffering from chronic diseases in 2020, while in 2019, chronic conditions caused 88.5% of mortalities in the country. The country’s geriatric population and the prevalence of chronic illnesses are increasing. Approximately 80% of deaths among the people aged 60 years in the country are caused due to chronic NCDs, of which the most severe are ischemic heart disease, stroke, chronic obstructive pulmonary disease (COPD), and type II diabetes. The incidence of chronic diseases such as cancer, diabetes, cardiovascular diseases (CVDs), and tuberculosis is increasing in the country due to rapid urbanization, which is expected to surge the demand for immunodiagnostic tests.

APAC Immunodiagnostic Market Revenue and Forecast to 2028 (US$ Million)

APAC Immunodiagnostic Market Segmentation

The APAC immunodiagnostic market is segmented into product, clinical indication, end user, and country.

Based on product, the APAC immunodiagnostic market is segmented into enzyme-linked immunosorbent assays (ELISA), chemiluminescence immunoassays (CLIA), radioimmunoassay (RIA), and others. The enzyme-linked immunosorbent assays (ELISA) segment registered the largest market share in 2022.

Based on clinical indication, the APAC immunodiagnostic market is segmented into infectious diseases, hepatitis+HIV, endocrinology, gastrointestinal, metabolics, and others. The infectious diseases segment registered the largest market share in 2022.

Based on end user, the APAC immunodiagnostic market is segmented into hospitals, clinics, diagnostics laboratories, academic and research institutes, and others. The hospital segment registered the largest market share in 2022.

Based on country, the APAC immunodiagnostic market is segmented into China, Japan, India, Australia, South Korea, and the Rest of APAC. China dominated the market in 2022.

Abbott Laboratories; bioMerieux SA; Danaher Corp; DiaSorin S.p.A.; F. Hoffmann-La Roche Ltd; PerkinElmer Inc.; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; Siemens Healthineers AG; Svar Life Science AB; and Thermo Fisher Scientific Inc are the leading companies operating in the APAC immunodiagnostic market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the APAC immunodiagnostics market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the APAC immunodiagnostics market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth APAC market trends and outlook coupled with the factors driving the immunodiagnostics market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution